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A CHRONIC PROBLEM:  
PAIN MANAGEMENT OF  
NON-CANCER PAIN IN AMERICA 
SIGRID FRY-REVERE* 
ELIZABETH K. DO** 
Pain can have debilitating effects on an individual. It can erode an 
individual‘s quality of life1 as well as his or her ability to earn an income.2 In cases 
where chronic pain is inadequately treated, patients can develop difficulties 
functioning.3 They become less involved with their friends and family4 and often 
suffer from poor attendance records at work.5 It is estimated that the cost of chronic 
pain in the U.S. is approximately $600 billion annually,6 yet at least 116 million 
Americans with the condition continue to be under-treated.7 A study conducted by 
the World Health Organization found that sufferers of chronic pain are more than 
four times as likely to suffer from depression and anxiety disorders.8 
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 1. See PATRICIA W. IYER, MEDICAL-LEGAL ASPECTS OF PAIN AND SUFFERING 316 (2003). 
 2. See AAPM Facts and Figures on Pain: Lost Productive Time and Cost Due to Common Pain 
Conditions in the United States Workforce, AM. ACAD. PAIN MED., 
http://www.painmed.org/patientcenter/facts_on_pain.aspx#lost (last visited Feb. 27, 2013) (reporting the 
average number of productive hours lost per week among workers in the United States as a result of 
common pain conditions). 
 3. See Michael A. Ashburn & Peter S. Staats, Management of Chronic Pain, 353 LANCET 1865, 
1865 (1999) (noting that individuals with chronic pain often experience depression, fatigue, and overall 
decreased bodily functioning). 
 4. See Jane E. Brody, Chronic Pain: A Burden Often Shared, N.Y TIMES, Nov. 13, 2007, 
http://www.nytimes.com/2007/11/13/health/13brod.html?_r=0 (noting that the anxiety and stress that 
individuals experiencing chronic pain encounter is generally also shared by family members and 
friends). 
 5. See Anne-Marie Vidal, The Politics of Pain: The Controversy Surrounding Chronic Pain and 
Opioids, PROHEALTH (Nov. 15, 2002), http://www.prohealth.com/library/showarticle.cfm?libid=8932. 
 6. Salynn Boyles, 100 Million Americans Have Chronic Pain, CBS NEWS (June 30, 2011, 5:31 
PM), http://www.cbsnews.com/stories/2011/06/30/health/webmd/main20075918.shtml. 
 7. Maia Szalavitz, Report: Chronic, Undertreated Pain Affects 116 Million Americans, TIME (June 
29, 2011), http://healthland.time.com/2011/06/29/report-chronic-undertreated-pain-affects-116-million-
americans/. 
 8. Vidal, supra note 5. 
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In order to address the disparity in chronic pain management, the United 
States Congress declared the years from 2001 through 2010 the ―Decade of Pain 
Control and Research.‖9 Despite such initiatives, our healthcare system is still in 
need of improved pain management techniques.10 Social barriers, particularly 
related to the prescription and usage of opioids, hinder our ability to help millions 
of Americans suffering from chronic (non-cancer) pain.11 For example, although 
opioids are widely accepted as an appropriate treatment of cancer pain, pain at end-
of-life, and acute pain,12 use of opioids for chronic, non-malignant pain remains an 
issue of considerable debate.13 Such issues need to be addressed, but not by 
restricting access to effective pain management.14 There is no quick fix for the pain 
management crisis.15 Promotion of a better understanding among the general public 
is the primary step that needs to be taken towards better advocacy for those 
suffering from chronic pain.16  
This article addresses the advocacy needs in pain management. The three core 
barriers to effective treatment are: A) misinformation regarding chronic pain and its 
management, B) fears of addiction, and C) restrictive drug control legislation. Part I 
explains the barriers to effective treatment, which include misinformation regarding 
chronic pain and its management, fears of addiction by both patients and 
physicians, and restrictive drug control legislation. Part II suggests ways to 
overcome these barriers. These solutions include actions to minimize and transcend 
these barriers that can be taken by patients, their families, healthcare workers, 
legislators and policymakers. 
 
 9. Frank Brennan et al., Pain Management: A Fundamental Human Right, 105 ANESTHESIA & 
ANALGESIA 205, 208 (2007). 
 10. Boyles, supra note 6. 
 11. Id. 
 12. B.-J. Collett, Chronic Opioid Therapy for Non-Cancer Pain, 87 BRIT. J. ANAESTHESIA 133, 
133–34 (2001) (discussing the widespread use of opioids for treating various levels of pain in several 
countries). 
 13. Michael Clark, Benefits and Risks of Opioids in Arthritis Management, JOHNS HOPKINS 
ARTHRITIS CENTER, http://www.hopkinsarthritis.org/patient-corner/disease-management/benefits-and-
risks-of-opioids-for-chronic-pain-management/ (last updated July 31, 2012). 
 14. See Penney Cowan, The Myths of Pain Control, CHRONICLE (Am. Chronic Pain Ass‘n, Rocklin, 
Cal.), Fall 2006, at 1, available at http://www.theacpa.org/uploads/documents/chronicle 
_fall06_82806.pdf (acknowledging that while they are not for everyone, opioids can be effective in 
providing pain relief).  
 15. See generally David E. Joranson & Karen M. Ryan, Ensuring Opioid Availability: 
Methods and Resources, 33 J. PAIN & SYMPTOM MGMT. 527, 531–32 (2007) (explaining that fear of 
addiction, strict drug control laws, and lack of education create barriers to the availability of opioids as a 
treatment method). 
 16. INST. OF MED., RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, 
CARE, EDUCATION, AND RESEARCH 1, 4 (2011) (presenting findings and recommendations as to how to 
change education and research to better address pain in the United States). 
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I.  BARRIERS TO EFFECTIVE TREATMENT 
A.  Misinformation Regarding Chronic Pain 
The first of these three core barriers seems to be rooted in social 
misconceptions related specifically to the role of pain in everyday life and opioids 
that can be used to relieve it. In the United States, there is the widespread 
misperception that physical dependence is the same as addiction to opioids.17 The 
continued lack of distinction can be partly attributed to the inaccurate use of these 
terms in the realms of professional education and narcotic control laws at both the 
national and international levels.18 Social misconceptions about chronic pain result 
from confused terminology, in that there is a lack of distinction between ―physical 
dependence‖ and ―addiction,‖19 as well as perpetuated fears of addiction20 and 
restrictive drug control legislation utilizing the same confused terminology.21 
While ―addiction‖ is often used interchangeably with ―physical dependence,‖ 
they should not hold the same negative connotations.22 Although both terms are 
used to refer to a patients‘ biological and/or psychological need for a substance to 
feel good, normal, or better, in this article the term ―addiction‖ will exclusively 
refer to the type of physical and psychological dependence leading to criminal or 
self-destructive behaviors.23 Meanwhile, ―physical dependence,‖ commonly 
referred to as ―drug dependence‖ or ―tolerance,‖ will be used to describe a 
biological and/or psychological need for a substance (in this case, opioids) to feel 
normal, good, or better, but not by definition a state of being anti-social or prone 
towards criminality or violence.24  
 
 17. See Robert L. Fine, Ethical and Practical Issues with Opioids in Life-Limiting Illness, 20 
BAYLOR U. MED. CENTER PROC. 5, 7–8 (2007). 
 18. See June L. Dahl, Working with Regulators to Improve the Standard of Care in Pain 
Management: The U.S. Experience, 24 J. PAIN & SYMPTOM MGMT. 136, 142 (2002) (discussing the 
confusion among many health care providers regarding the definitions of addiction and tolerance and the 
failure of most medical schools to educate students about pain management); cf. Martha A. Maurer et 
al., Federal and State Policies at the Interface of Pain and Addiction, in PAIN AND CHEMICAL 
DEPENDENCY 377, 377 (Howard S. Smith & Steven D. Passik eds., 2008) (noting the crucial need for 
health care providers to understand and accurately the terminology surrounding addiction and pain, 
especially as they relate to the law). 
 19. See Fine, supra note 17, at 7–8. 
 20. See Myths and Misconceptions Surrounding Addiction in Chronic Pain Patients Treated with 
Opioid Analgesics, PAIN LIVE (Oct. 11, 2011), http://www.painlive.com/publications/pain-
management/2011/september-2011/Myths-and-Misconceptions-Surrounding-Addiction-in-Chronic-
Pain-Patients-Treated-with-Opioid-Analgesics. 
 21. See Maurer et al., supra note 18, at 377.  
 22. See Fine, supra note 17, at 7–8. 
 23. See NAT‘L INST. ON DRUG ABUSE, MEDIA GUIDE 2 (2011), available at 
http://www.drugabuse.gov/sites/default/files/mediaguide_web_1.pdf (discussing the difference between 
the terms physical dependence and addiction). 
 24. Id. The distinction this article makes between ―addiction‖ as bad and ―dependence‖ and 
―tolerance‖ as morally neutral is essential to maintaining clarity in what is being discussed throughout 
this article, namely that physical dependence does not by necessity imply anti-social behavior, but quite 
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The lack of distinction between these terms contributes to inadequate 
treatment of pain relief by perpetuating the second core barrier: the fear that even 
prescription use of pain medications will lead to the socially unacceptable 
behaviors usually associated with addiction.25 The difference between addiction 
and dependence is related to the after-effects of drug use: patients with chronic pain 
experiencing improved function with drugs are ―opioid-dependent‖ while those 
who do not show improved functioning, but instead display anti-social behaviors 
are considered ―opioid-addicted.‖26 According to national pain experts, opioid 
addiction can be described as a ―primary chronic, neurobiological disease, with 
genetic psychosocial, and environmental factors influence its development and 
manifestations. It is characterized by behaviors that include one or more of the 
following: impaired control over drug use, compulsive use, continued use despite 
harm, and craving.‖27 Using DSM-III-R criteria, Hoffman and colleagues found 
that of chronic-pain patients, 1.9% misused analgesics and 12.6% were analgesic 
dependent.28  
Meanwhile, the third core barrier, restrictive drug control legislation, 
reinforces these misconceptions (and continues the trends of inadequate pain 
management) by using the same confused terminology and creating an environment 
that punishes physicians and other healthcare providers for prescribing opioids that 
could potentially aid patients relieve their pain.29 
 
the contrary when it comes to pain management. See Srdjan S. Nedeljkovic et al., Assessment of Efficacy 
of Long-Term Opioid Therapy in Pain Patients with Substance Abuse Potential, 18 CLINICAL J. PAIN 
S39, S43 (2002) (finding that the majority of patients receiving long-term opioid therapy in one study 
experienced increased activity levels). Yet, since some people associate any drug use with negative 
social behaviors, this article relegates the term that means dependence and bears the most negative 
connotations to situations where dependence has in fact lead to negative social behaviors. See e.g., Jerry 
Shaw, Negative Effects from Drug Abuse, LIVESTRONG (Sept. 28, 2010), http://www.livestrong.com/ 
article/254271-negative-effects-from-drug-abuse/ (discussing the negative effects of drug abuse). 
 25. See Fine, supra note 17, at 7–8. 
 26. Scott Fishman, Addiction vs. Dependence on Pain Medications, DISCOVERY HEALTH, 
http://health.howstuffworks.com/diseases-conditions/pain/medication/addiction-v-dependence-on-pain-
medications.htm (last visited Mar. 29, 2013). 
 27. Jette Højsted & Per Sjøgren, Addiction to Opioids in Chronic Pain Patients: A Literature 
Review, 11 EUR. J. PAIN 490, 492 (2007). 
 28. Norman G. Hoffman et al., Prevalence of Abuse and Dependency in Chronic Pain Patients, 30 
INT. J. ADDICTIONS 919, 923 (1995). 
 29. See Diederik Lohman et al., Access to Pain Treatment as a Human Right, BMC MED., 2, 4, 5 
(Jan. 2010), http://www.biomedcentral.com/content/pdf/1741-7015-8-8.pdf (identifying restrictive drug 
control legislation and enforcement practices as a barrier to access to pain management).  
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B.  Fears of Addiction  
1.  Patients’ Fears of Addiction  
Since patients that live with chronic pain often experience comorbidities like 
depression and anxiety,30 in addition to possible disturbances in sleep cycles,31 
decreased cognitive and physical functioning,32 and other disruptions of daily living 
which decrease the quality of life for patients and those around them, society has 
much to gain from pain management regiments.33 Usually this is accomplished 
through the continuous suppression of pain through use of analgesic therapies such 
as non-opioid analgesics and opioids analgesics.34 The latter are generally stronger 
and used for more severe chronic pain.35 However, despite their general 
effectiveness, opioids have not traditionally been patients‘ primary choice of 
treatment in combating chronic pain.36  
Opioids have historically been associated with addiction.37 Studies have 
shown that if prescribed and used correctly, opioids can be highly effective in 
treating a broad range of pain across different populations.38 However, researchers 
have also found that certain groups of patients are at risk of addiction and abuse.39 
The exact risk of abuse remains uncertain, however, prevalence estimates of 
addiction within chronic non-malignant pain patients range from zero to fifty 
percent.40 Additionally, recent epidemiological studies have found that patients 
receiving higher doses of medically prescribed opioids for chronic pain are at 
 
 30. See Bruce Nicholson & Sunil Verma, Comorbidities in Chronic Neuropathic Pain, 5 PAIN 
MED. S9, S10–S11 (2004). 
 31. See Qian Chen et al., Characteristics of Chronic Pain Associated with Sleep Difficulty in Older 
Adults: The Maintenance of Balance, Independent Living, Intellect, and Zest in Elderly (MOBILIZE) 
Boston Study, 59 J. AM GERIATRICS SOC‘Y 1385, 1385–87 (2011). 
 32. See Tamara A. Baker et al., Factors Influencing Chronic Pain Intensity in Older Black Women: 
Examining Depression, Locus of Control, and Physical Health, 17 J. WOMEN‘S HEALTH 869, 874 
(2008) (finding that decreased physical functioning correlated with increased pain in a sample of black 
women experiencing chronic pain); Shulamith Kreitler & David Niv, Cognitive Impairment in Chronic 
Pain, PAIN: CLINICAL UPDATES (Int‘l Ass‘n for the Study of Pain, Seattle, Wash.), July 2007, at 2–3 
(revealing that patients with chronic pain in one sample also experienced cognitive difficulties such as 
lower attention span, decreased verbal abilities, and mental flexibility and memory deficits). 
 33. See generally Warren A. Katz & Robert L. Barkin, Dilemmas in Chronic/Persistent Pain 
Management, 56 DISEASE-A-MONTH 233, 233–34 (2010). 
 34. See NAT‘L PHARMACEUTICAL COUNCIL, PAIN: CURRENT UNDERSTANDING OF ASSESSMENT, 
MANAGEMENT, AND TREATMENTS 33, 38 (2001). 
 35. Id. at 38. 
 36. See Katz & Barkin, supra note 33, at 240, 244. 
 37. See Fine, supra note 17, at 7. 
 38. See Collett, supra note 12, at 133, 134 (discussing patient surveys and case reports that support 
the effectiveness of opioids for treating various types of pain).  
 39. See Joy R. Goebel et al., Addressing Patients’ Concerns About Pain Management and 
Addiction Risks, 11 PAIN MGMT. NURSING 92, 92–93 (2010).  
 40. Højsted & Sjøgren, supra note 27, at 507. 
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increased risk for overdose, when compared to patients receiving lower doses.41 
Other groups at high risk of addiction include individuals diagnosed with non-
opioid substance abuse, males (particularly of younger ages), and those with mental 
health disorders.42 
Another explanation for the lack of opioid use among chronic pain patients is 
rooted in the idea that pain is a part of the human condition that people should not 
rush to relieve. For example, some individuals perceive pain to be necessary, 
natural, and (at times) beneficial in the sense that its presence is essential in the 
diagnosis of health ailments.43 By treating pain, rather than the underlying ailment 
causing the pain, some patients fear that they are putting their health at risk of 
worsening in the future.44 
A third explanation can be found in the idea that pain is a positive means of 
building character. This remains a common belief among both religious and non-
religious people.45 In one study, it was found that approximately one-third of 
patients agreed with the belief that pain builds character.46 However, the same 
study found that this has an insignificant effect on the under treatment of pain.47 
A fourth explanation for why opioid use is lacking among chronic pain 
patients is the idea that opioids should be and/or are only prescribed for cancer 
patients or patients that are near death.48 Patients fear that opioid treatments could 
impair their quality of life more than their current level of pain, primarily through 
unintended consequences (e.g. substance dependency49 or effects on mental and 
physical health).50 
A fifth explanation can be found in the belief held by some individuals that 
opioid use is acceptable, but only in cases where doses are correlated to the severity 
of the disease, rather than the intensity of pain.51
 
 
 41. E.g., Kate M. Dunn et al., Opioid Prescriptions for Chronic Pain and Overdose, 152 ANNALS 
INTERNAL MED. 85, 90 (2010) (reporting in one study that patients receiving higher doses of opioids for 
chronic non-cancer pain were at greater risk of overdose than patients receiving lower doses). 
 42. See Goebel et al., supra note 39, at 93. 
 43. See Brennan et al., supra note 9, at 208 (discussing the cultural myth that pain is an inevitable 
and natural part of the human experience).  
 44. Id. at 209.  
 45. See Otto F. Weis et al., Attitudes of Patients, Housestaff, and Nurses Toward Postoperative 
Analgesic Use, 62 ANESTHESIA & ANALGESIA 70, 73 (1983). 
 46. Id. 
 47. Id. 
 48. See Russell K. Portenoy et al., Opioid Use and Survival at the End of Life: A Survey of a 
Hospice Population, J. PAIN & SYMPTOM MGMT. 532, 533 (2006). 
 49. See Brennan, supra note 9, at 209. 
 50. See Collett, supra note 12, at 135–36. 
 51. See Mark Sullivan & Betty Ferrell, Ethical Challenges in the Management of Chronic 
Nonmalignant Pain: Negotiating Through the Cloud of Doubt, 6 J. PAIN 2, 7 (2005) (arguing that pain 
relief should be provided regardless of whether pain is proportional to the disease in question). 
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Finally, a sixth explanation for the lack of opioid use to treat chronic pain is 
the fear of stigmatization.52 This issue is a separate one from whether or not the 
patient and/or his or her family believe that opioid use results in addiction; rather, 
this explanation focuses on whether or not they believe others believe it does.53  
2.  Physicians’ Fears of Enabling Criminal Behavior 
Physicians and other healthcare providers are accustomed to taking into 
consideration the risks and benefits of prescribing medications, particularly when 
weighing the benefits of treatment versus the risks of potential adverse effects.54 
However, in the case of opioids, the boundaries are not always clear.55 Although 
the prescription of opioids does provide chronic pain patients with short-term 
and/or immediate relief of pain symptoms, opioids also provide the opportunity for 
potential misuse by the patient, possibly leading to addiction.56 
Physicians‘ choices regarding the prescription of opioids for chronic pain 
patients are shaped by a number of factors. Physicians‘ fears of addiction 
developing in their chronic pain patients due to opioid usage, particularly within 
patients with substance misuse/abuse histories, is one such factor.57 Another is their 
fear of legal repercussions for the over-prescription of opioids for chronic pain 
relief.58 Physicians also consider how persistent and uncontrolled pain might affect 
a patient in the long-term when opioids treat pain in the short-term.59 Finally, 
physicians face fears that under certain social conditions, patients‘ medication may 
be distributed illegally either by the patient or another individual with access to the 
prescribed opioids.60 
 
 52. See Brennan, supra note 9, at 208. 
 53. See id. 
 54. See Goebel et al., supra note 39, at 92–93 (elaborating on the process that clinicians use to 
determine pain treatment options for patients).  
 55. Bhushan Bhamb et al., Survey of Select Practice Behaviors by Primary Care Physicians on the 
Use of Opioids For Chronic Pain, 22 CURRENT MED. RES. & OPINION 1859, 1864 (2006) (noting that 
physicians have different comfort levels in prescribing narcotics). 
 56. See Goebel et al., supra note 39, at 92–93. 
 57. Alex Baldacchino et al., Guilty Until Proven Innocent: A Qualitative Study of the Management 
of Chronic Non-cancer Pain Among Patients with a History of Substance Abuse, 35 ADDICTIVE BEHAV. 
270, 270–71 (2010) (finding that physicians were more hesitant to prescribe opioids to patients who had 
a history of substance abuse). 
 58. See Brennan, supra note 9, at 209. 
 59. See Rollin M. Gallagher & Lisa J. Rosenthal, Chronic Pain and Opiates: Balancing Pain 
Control and Risks in Long-Term Opioid Treatment, 89 ARCHIVES PHYSICAL MED. REHABILITATION 
S77, S78 (2008) (discussing the limited data regarding long-term opioid use, but noting that the 
evidence that does exist is generally positive). 
 60. See Howard L. Fields, The Doctor’s Dilemma: Opiate Analgesics and Chronic Pain, 69 
NEURON 591, 591 (2011) (discussing physician concerns in prescribing opioids including the potential 
for abuse and illegal distribution).  
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Like patients, physicians fear their patients may become addicted.61 This fear 
has an effect on the way physicians prescribe opioids.62 For example, physicians 
have been found to be especially reluctant to prescribe opioids when their patients 
have a history of substance abuse.63 The rise of abuse of opioids and other 
prescription drugs among patients may be fueling these fears.64 So much, in fact, 
that legal action has been taken by the government to limit physicians‘ ability to 
distribute opioids.65 
The United States currently has a federal and state regulatory framework that 
creates a closed distribution system, whereby state-licensed and federally registered 
practitioners and researchers have the ability to prescribe and dispense opioids.66 
Under the ―unlawful diversion statute,‖ it is a federal felony to ―knowingly and 
intentionally acquire, or aid and abet someone else in acquiring a controlled 
substance by misrepresentation, fraud, forgery, deception, or subterfuge.‖67 This 
includes the unlawful distribution of a controlled substance by a medical 
practitioner outside ―the usual course of medical practice‖68 and is punishable by up 
to four years imprisonment and a $250,000 fine.69 According to Title 21, U.S. 
Code, Section 841(a)(1), if a person, including a medical practitioner ―knowingly 
or intentionally. . . manufacture[s], distribute[s], or dispense[s], or possess[es] with 
intent to manufacture, distribute, or dispense, a controlled substance‖70 he or she is 
also guilty of a felony and faces a imprisonment for up to twenty years, a $1 
million fine, and a period of supervised release following imprisonment of up to 
three years.71 
 
 61. See ALFRED V. ANDERSON ET AL., OPIOID PRESCRIBING: CLINICAL TOOLS AND RISK 
MANAGEMENT STRATEGIES 2 (2009). 
 62. Id. at 14. 
 63. See, e.g., Baldacchino et al., supra note 57, at 271.  
 64. See generally OFFICE OF NAT‘L DRUG POL‘Y, OFFICE OF THE PRESIDENT, EPIDEMIC: 
RESPONDING TO AMERICA‘S PRESCRIPTION DRUG ABUSE CRISIS, EXECUTIVE OFFICE OF THE PRESIDENT 
OF THE UNITED STATES (2011) (providing an overview of the prescription drug abuse problem and 
offering strategies to curb its rise).  
 65. See, e.g., Kevin B. O‘Reilly, States Try More Aggressive Rx Opioid Controls, AM. MED. NEWS 
(Oct. 17, 2011), http://www.ama-assn.org/amednews/2011/10/17/prl21017.htm (discussing actions taken 
in several states to curb prescription of opioids). 
 66. See DAVID JORANSON, CTR. FOR LAWFUL ACCESS & ABUSE DETERRENCE, THE EFFICACY OF 
FDA OPIOID-SPECIFIC REMS: A COMMENTARY 1 n.2 (2010), available at 
http://claad.org/downloads/Product-specific%20REMS%20commentary%20012510.pdf.  
 67. 21 U.S.C. § 843(a)(3) (2011). 
 68. 21 C.F.R. § 1306.04(a) (2012). See also 21 U.S.C. § 822(b) (2011) (authorizing practitioners to 
dispense controlled substances in compliance with the CSA and ―to the extent authorized by their 
registration‖).  
 69. 21 U.S.C. § 843(d)(1) (2011). 
 70. § 841(a).  
 71. § 841(b). 
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However, since the regulatory authority over the practice of medicine is 
entrusted to state medical licensing boards, actual punishments will vary by state.72 
For example, a lesser charge for unlawful diversion would be a violation of Title 
21, U.S. Code, Section 844, a federal misdemeanor statute.73 However, previous 
convictions of medical practitioners have resulted in the suspension and/or 
revocation of Drug Enforcement Administration (DEA) licenses, significant 
monetary fines, and probationary periods.74 Such legal action has directly affected 
the way physicians prescribe pain medication in that they are choosing to be risk 
adverse, that is, intentionally under-medicate pain patients.75  
It should also be mentioned that countervailing pressures to prescribe 
medications also exist. These pressures may be created out of desires to treat pain 
more ―compassionately‖76 and the growing belief that pain is ―indicative of 
pathology and therefore amenable to treatment.‖77 For example, there have been 
cases where medical boards have made medical malpractice decisions when doctors 
failed to prescribe opioids for chronic pain.78 However, while these legal actions 
against opioid prescribers have occurred, they are the outlying cases.79 
The choice to under-medicate pain patients also stems from physician and 
healthcare providers‘ fears that they may be unintentionally enabling criminal 
behavior by prescribing opioids to their patients.80 According to a 2009 National 
Survey on Drug Use and Health, among persons aged twelve or older who used 
pain relievers non-medically, over sixty percent got the drug from a friend, relative, 
drug dealer, or the Internet.81 In other words, those abusing pain relievers are not 
the same individuals who are receiving prescriptions for them. Thus, in order to 
 
 72. See JORANSON, supra note 66, at 4.  
 73. 21 U.S.C. § 844 (2011); see also Ronald J. Friedman, Increased Scrutiny of Medical Providers: 
A Cause for Reflection and Diligence, PAIN PRACTITIONER, Summer 2010, at 26, 27. 
 74. See Friedman, supra note 73, at 27. 
 75. See id. at 33 (concluding that fear of prosecution and fines has had a ―chilling effect‖ on how 
doctors prescribe medication). 
 76. Christine S. Moyer, Physicians Struggle to Treat Pain Amid Opioid Overdose Crisis, AM. MED. 
NEWS (Nov. 14, 2011), http://www.ama-assn.org/amednews/2011/11/14/prl21114.htm. 
 77. Anna Lembke, Why Doctors Prescribe Opioids to Known Opioid Abusers, 367 NEW ENG. J. 
MED. 1580, 1580 (2012). 
 78. See, e.g., Bergman v. Chin, No. H2057321, 2001 WL 1517376 (Cal. App. Dep‘t Super. Ct. 
June 13, 2001) (finding that a doctor‘s conduct was reckless where he refused to provide appropriate 
pain medication to an elderly patient experiencing ―out of control‖ pain).  
 79. See, e.g., Hoover v. Agency for Health Care Admin., 676 So. 2d 1380, 1381 (Fla. Dist. Ct. App. 
1996) (discussing actions taking against a physician for inappropriate and excessive prescribing of 
Schedule II controlled substances to patients). 
 80. See Fields, supra note 60, at 592 (explaining how a doctor‘s decision to prescribe pain killers is 
complicated by the difficulty of determining when a patient is pretending to be in pain).  
 81. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & HUMAN 
SERVS., RESULTS FROM THE 2009 NATIONAL SURVEY ON DRUG USE AND HEALTH 28 (2010). 
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restrict the diversion of opioids and other pain relievers, some physicians and 
healthcare providers may choose to limit the amount prescribed.82  
The chilling effect on proper treatment is understandable when even one 
patient who becomes addicted could lead to an expensive, time consuming, and 
potentially reputation ruining investigation, even if eventually it is concluded that 
the physician did not ―knowingly‖ cause the illegal ―distribution of a controlled 
substance.‖83 Even worse, just prescribing ―outside the usual course of medical 
practice,‖ which could mean more than the average dose for a particular patient, or 
treating more pain patients than other doctors, could trigger an investigation.84 
Thus, physicians and healthcare providers have to make some difficult decisions 
when treating chronic pain patients, the first of which is whether or not to prescribe 
opioids at all, even if they are likely to be the best possible treatment for the patient 
in question.85 
The legal risks are compounded by the medical complexities of treating 
someone with opioids.86 Although prescribing opioids will reduce pain 
immediately, it is only a ―quick fix‖ in that the amount prescribed will only work 
for a certain amount of time before the body builds up its own tolerance level, and 
higher doses are needed to relieve pain.87 Thus, physicians have to weigh the risks 
and benefits of persistent and uncontrolled pain in the long-term versus the risks 
and benefits of prescribing opioids in the short-term within a small amount of time, 
as a patient‘s pain endures.88 Greater dosages also require more intensive 
monitoring on the part of the physician or healthcare provider because prolonged 
use of opioids may affect cognition and psychomotor functioning.89  
C.  Restrictive Drug Control Legislation 
Although a bulk of the debate regarding chronic pain and opioid usage 
revolves around physician/patient relations, outside agencies also influence the 
dynamics of the debate. Agencies such as the DEA and state medical boards can 
affect the way physicians approach pain management through potential or 
 
 82. See Fields, supra note 60, at 591 (stating that doctor awareness of opioid abuse has resulted in 
their hesitancy in prescribing them to patients, particularly for long periods of time or for high dosages). 
 83. See Friedman, supra note 73, at 32–33 (suggesting ways a physician can protect his or her 
reputation and medical practice from the devastating impact of government investigations).  
 84. See id. at 31–32. 
 85. See Fields, supra note 60, at 591. 
 86. See Henry McQuay, Opioids in Pain Management, 353 LANCET 2229, 2229–30 (1999) 
(explaining the varying adverse side effects that may occur from opioid use). 
 87. See id. at 2230–31 (discussing tolerance issues surrounding pain medication). 
 88. George R. Hansen, Management of Chronic Pain in the Acute Care Setting, 23 EMERGENCY 
MED. CLINICS N. AM. 307, 312, 319 (2005). 
 89. See id. at 319–22 (discussing the importance of physician monitoring of patients to prevent 
adverse side effects from long term and greater dosages of opioids).  
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perceived regulatory disciplinary measures.90 These outside agencies influence the 
way physicians prescribe opioids for chronic pain patients by investigating 
prescribers of opioids,91 placing physicians at risk of sanction for over-prescribing 
opioids,92 and providing no disincentives or punishments for under-treatment of 
chronic pain.93 Studies suggest that fears of regulatory punishment (i.e. criminal 
prosecution) are the most frequently cited reason that physicians choose not to 
provide adequate treatment for chronic pain via the prescription of opioids.94 
The DEA has steadily increased the amount of resources dedicated to 
investigating the diversion of controlled pharmaceuticals, such as opioids, since the 
findings of a report by the United States House of Representatives that was 
published in 2005.95 In this report, the House discussed the ―lack of effort to 
address this problem [of identifying prescription drug abuse]‖ made by the DEA.96 
Despite the DEA taking steps to improve its reputation by working to control 
prescription drug abuse, several shortcomings identified in 2002 still remain, 
according to a 2006 Justice Department Office of the Inspector General‘s report.97 
Consequently, the DEA continues to feel the pressure to perform and has since 
moved from working to control pharmaceutical diversion over the Internet to 
investigating the physicians who prescribe controlled pharmaceuticals.98 
According to Title 21, U.S. Code, Section 827(a)(3), all medical practitioners 
are required to maintain an accurate and up-to-date record of distribution of 
controlled substances,99 which are subject to audit and administrative inspection by 
the DEA.100 In the past, physicians have been investigated by the DEA and tried for 
such criminal offenses as conspiracy to engage in drug trafficking,101 healthcare 
 
 90. See M.M. Reidenberg & O. Willis, Prosecution of Physicians for Prescribing Opioids to 
Patients, 81 CLINICAL PHARMACOLOGY & THERAPEUTICS 903, 903 (2007). 
 91. See id. 
 92. See id. at 905 (noting that state medical boards have the authority to refer physicians who over-
prescribe opioids to the criminal justice system for prosecution).  
 93. See Ann M. Martino, In Search of a New Ethic for Treating Patients with Chronic Pain: What 
Can Medical Boards Do?, 26 J.L. MED. & ETHICS 332, 332–33 (1998) (explaining that although 
physicians are subject to sanctions for over prescribing, there is no such risk for under prescribing). 
 94. See id. at 332.  
 95. See Laxmaiah Manchikanti, National Drug Control Policy and Prescription Drug Abuse: Facts 
and Fallacies, 10 PAIN PHYSICIAN 399, 414 (2007) (―Consequently the DEA increased the amount of 
resources and manpower dedicate to investigating the diversion of controlled pharmaceuticals.‖). 
 96. H.R. REP. NO. 108-576, at 28 (2004). 
 97. OFFICE OF THE INSPECTOR GEN., U.S. DEP‘T OF JUSTICE, EVALUATION & INSPECTIONS DIV., 
U.S. DEPT. OF JUSTICE, NO. I-2006-004, FOLLOW-UP REVIEW OF THE DRUG ENFORCEMENT 
ADMINISTRATION‘S EFFORTS TO CONTROL THE DIVERSION OF CONTROLLED PHARMACEUTICALS III 
(2006). 
 98. Id. at 5.  
 99. 21 U.S.C. § 827(a)(3) (2011). 
 100. § 880(b)(1). 
 101. See e.g., Andrew Welsh-Huggins, Autopsy: Accused Ohio Pill Mill Doctor Facing Trial 
Committed Suicide by Drug Overdose, THE REPUBLIC (Nov. 8, 2012), http://www.therepublic.com/ 
view/story/314d7bc92ef040ce922f448d54624dbf/OH--Drug-Deaths-Doctors-Suicide (explaining the 
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fraud,102 drug-trafficking resulting in serious bodily injury,103 and drug-trafficking 
resulting in death104—all related to the choices they made in their prescription 
practices—and were forced to face the legal consequences of their perceived 
criminal actions, whether they were in fact guilty or not. 
Meanwhile, state medical boards influence physicians‘ prescription practices 
by punishing what they see as bad behavior.105 However, studies have shown that 
state medical boards are only likely to take away licenses to practice medicine from 
physicians following prosecution, rather than before.106 According to a 2007 study, 
fifty-three doctors were indicted or convicted of criminal activities related to 
opioids in 2004 and 2005.107 Of these cases, thirty-two criminal charges were based 
on allegations of prescribing opioids outside of the bounds of normal medical 
practice.108 In only two of these cases were state medical boards willing to make 
judgment prior to criminal action.109 Since this study utilized media resources,110 it 
is possible that state medical board actions are sensitive to the media, particularly if 
the media projects any sort of unprofessionalism among pain physicians that will 
reflect poorly on state medical boards and/or the medical profession.111 Either way, 
the fact that any physicians have lost their licenses without first being first 
 
severity of the charges the doctor faced, including ―conspiracy to engage in corrupt activity [and] 
funding drug trafficking,‖ after allegedly writing ―more than 14,000 prescriptions‖ during a nine-month 
period while operating a clinic that was only open thirty-six hours per week). 
 102. See e.g., Carl Lietz, Court of Appeals Affirms Life Sentences for Pain Management Physician 
(and Creates Circuit Split), FED. CRIM. LAWYER BLOG (Sept. 20, 2011), 
http://www.georgiafederalcriminallawyerblog.com/health_care_fraud/ (discussing charges against a 
Florida doctor for health care fraud and unlawfully dispensing controlled substances). 
 103. See O‘Reilly, supra note 65. In September 2003, William E. Hurwitz, M.D. was charged with 
forty-nine counts, including drug-trafficking conspiracy to distribute oxycodone and other pain 
medications; and drug trafficking resulting in death and serious bodily injuries, along with health care 
fraud by a federal grand jury. Id. He was convicted on fifty counts of drug trafficking, including one 
count relating to death and serious bodily injuries in December 2004 and later sentenced to twenty-five 
years in federal prison and a fine of $1 million dollars. Id. 
 104. See e.g., Tina Rosenberg, Doctor or Drug Pusher?, N.Y. TIMES, June 17, 2007, § 6 (Magazine), 
at 48 (discussing a North Carolina doctor sentenced to 30 years in prison on several charges, including 
the charge of drug trafficking resulting in death when his patient died from taking prescribed OxyContin 
at fatal dosages). 
 105. See Diane E. Hoffmann & Anita J. Tarzian, Achieving the Right Balance in Oversight of 
Physician Opioid Prescribing for Pain: The Role of State Medical Boards, 31 J.L. MED. & ETHICS 21, 
21 (2003) (indicating that state medical boards have investigated and disciplined physicians for 
overprescribing, and that as a result physicians will inadequately prescribe opioids). 
 106. Reidenberg & Willis, supra note 90, at 904 (examining forty-seven cases involving criminal 
prosecution of doctors for opioid offenses, and finding that only two were reviewed by a state medical 
board prior to indictment).  
 107. Id. at 903. Study researchers reviewed media reports and journal articles to determine this 
number; thus, it only reflects published cases of doctors charged or convicted with opioid offenses. Id. 
 108. Id. at 904. 
 109. Id. 
 110. Id. at 903. 
 111. See Martino, supra note 93, at 332 (indicating that perception of regulatory risks to prescribing 
opioids far exceeds the reality).  
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convicted of a crime undoubtedly has a chilling effect on the prescription of 
opioids.112 
Consequently, physicians may need to deal with repeated requests for better 
pain management, but the brunt of under-medication is born by the chronic pain 
patients themselves, their families, friends, and work associates.113 Historically, 
there has been no risk of criminal prosecution, loss of professional privileges, or 
loss of reputation associated with telling a suffering patient that there is nothing 
more that can be done to help relieve his or her pain.114 In other words, incentives 
have been created for physicians to under-prescribe medications to prevent placing 
their ―livelihood, reputation, and status‖115 at stake through the regulatory action of 
medical boards and the DEA, but there is no countervailing risk associated with 
under-treating a patient in pain.116 As a result, physicians choose not to prescribe 
opioids as often as patients might need or want for their chronic pain in order to 
avoid potential legal repercussions.117 Thus, physicians find themselves in a 
balancing act that weighs the benefits of prescribing opioids to patients against the 
potential risk of being investigated by government agencies for trying to provide 
adequate treatment to their chronic pain patients.118 
II.  OVERCOMING BARRIERS TO EFFECTIVE TREATMENT OF CHRONIC PAIN 
The largest barrier to overcome is the misconceptions people have about the 
treatment of chronic pain with opioids. Fears of potential addiction continue to 
limit patients‘, family members‘, and physicians‘ willingness to consider opioids 
for the treatment of chronic pain.119 In order to overcome these barriers, advocacy 
 
 112. Id. (indicating that doctors second-guess decisions and under-prescribe out of a fear of being 
sanctioned for overprescribing opioids).  
 113. See Brody, supra note 4 (noting that the stress associated with chronic pain is often born by 
family and friends, as well as the patient themselves).  
 114. See Martino, supra note 93, at 332–33. But see Bergman v. Chin, No. H2057321, 2001 WL 
1517376 (Cal. App. Dep‘t Super. Ct. June 13, 2001) (finding that a physician‘s under-treatment of 
patient pain constituted elder abuse, despite the fact that there is no recognized cause of action for 
medical malpractice for under-treatment of pain).  
 115. Martino, supra note 93, at 338. 
 116. See supra note 115 and accompanying text.  
 117. See Martino, supra note 93, at 332 (indicating that physicians most often cite the fear of 
regulatory reprisal as the reason they under-treat chronic pain). 
 118. See Joyce S. Fontana, The Social and Political Forces Affecting Prescribing Practices for 
Chronic Pain, 24 J. PROF. NURSING 30, 30–31 (2008) (examining different factors, including physician 
fear of regulatory scrutiny, that have lead to inadequate prescribing practices for patients with chronic 
pain).  
 119. Margo McCaffery & Betty Rolling Ferrell, Correcting Misconceptions About Pain Assessment 
and Use of Opioid Analgesics: Educational Strategies Aimed at Public Concerns, 44 NURSING 
OUTLOOK 184, 186 (1996) (noting that patients, their family members, and the general public have fears 
of opioid addiction that pose barriers to effective pain management). 
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and education regarding chronic pain management is necessary.120 Misconceptions 
about opioid usage for chronic pain need to be addressed at the level of patients and 
their families, healthcare providers (especially physicians), and policymakers 
(legislators and agencies).121 
Misconceptions about opioid usage in chronic pain patients can be mitigated 
by understanding that the amount of medication required to treat pain varies from 
person to person, and over time in the same person. Thus, it is not possible to 
pinpoint a specific acceptable dose of opioids for chronic pain patients, but only a 
range of acceptable levels given the trajectory of each particular patient‘s pain 
relief.122 The actual amount prescribed to patients will vary, depending on: the 
degree of pain experienced, tolerance level, effectiveness of the treatment, and the 
amount of time the patient has been treated for chronic pain.123 It is even possible 
that tolerance varies over time, affecting the effectiveness of pain control 
differently at each stage of treatment.124 
Similarly, it is important to remember that the amount prescribed is not a sign 
that the physician is over-prescribing for a particular patient, as pain management is 
very patient specific.125 Nor is how often a physician prescribes pain medication to 
his patients a sign of over-prescribing; different physicians serve different patient 
populations and specialize in different conditions.126 Thus, the amount prescribed to 
patients, in and of itself, is not necessarily an indicator of potential addiction among 
 
 120. See AM. ACAD. FAM. PHYSICIANS, AMERICAN ACADEMY OF FAMILY PHYSICIANS PAIN 
MANAGEMENT AND OPIOID ABUSE: A PUBLIC HEALTH CONCERN 5–6 (2012), available at 
http://www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/painmanagement/painmanagement
opioids.Par.0001.File.tmp/Opioid%20Abuse%20Position%20Paper%20FINAL.pdf (noting that the 
American Academy of Family Physician seeks to find a solution to America‘s pain management 
problems through advocacy, collaboration, and education).  
 121. See McCaffery& Ferrell, supra note 119, at 186 (noting that misunderstandings about opiate 
addiction by patients, their families, and the general public result in the under-treatment of pain; it 
follows that misconceptions about opiates need to be addressed at these levels); Russell K. Portenoy & 
Seddon R. Savage, Clinical Realities and Economic Considerations: Special Therapeutic Issues in 
Intrathecal Therapy – Tolerance and Addiction, 14 J. PAIN & SYMPTOM MANAGEMENT S27, S32 (1997) 
(noting that physician‘s misconceptions about opioid addiction also result in the under-treatment of 
pain). 
 122. See Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain, AGENCY MED. 
DIRECTORS GROUP 3 (2010), http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf 
(recommending a dosing threshold for pain medication, but noting that effective pain management 
requires frequent assessments and tracking of pain relief). 
 123. See id. at 6–7; THE BRITISH PAIN SOC‘Y, OPIOIDS FOR PERSISTENT PAIN: GOOD PRACTICE 28 
(2010), available at http://www.britishpainsociety.org/book_opioid_main.pdf (indicating that factors 
such as a higher tolerance levels, increased pain intensity, or the development of an additional painful 
condition may require increased doses of opioids). 
 124. Id. 
 125. See, e.g., Rosenberg, supra note 106 (noting that ―‗[d]ose alone says nothing about proper 
medical practice‘‖ and that different patient populations may require significantly higher or lower 
doses). 
 126. Id. 
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a patient population.127 For addiction to exist, patients must also exhibit tendencies 
towards anti-social behavior.128 
A.  Advice for Patients and Their Families 
Patients and their families should work with their healthcare providers when 
deciding on the best treatment plan for their chronic pain. Patients can ensure that 
they receive adequate chronic pain management by being aware of their own 
personal and family medical histories, sharing this information with their 
physicians and other healthcare providers, being able to differentiate between 
tolerance and addiction when using opioids, and keeping careful record of their 
dosages and how they affect treatment success.129 
Patients need to be aware of their own personal medical histories, as well as 
their family medical history; this helps providers plan for potential risk for 
addiction or negative outcomes during treatment.130 Patients also need to disclose 
any history of substance abuse and/or family history of substance abuse prior to 
seeking prescriptions, while also being aware of when and if they are 
demonstrating potential addictive behaviors following use of opioids.131 Doing so 
does not mean the patient will not be treated, but will give the physician the 
opportunity to implement extra precautionary measures to monitor use and watch 
for possible abuse.132 
This information should be shared with healthcare providers, as a display of 
tendencies toward abuse requires close monitoring if and when opioids are 
prescribed for chronic pain.133 Although opioid-treated patients have been found to 
be less likely to develop addiction if they maintain a stable regime,134 as a cohort 
they present ―high rates of addiction comorbidity,‖ especially if they have a 
previous history with substance abuse.135 Thus, patients and their families should 
be aware of the common signs of drug abuse, such as increased usage, requests for 
 
 127. Id. 
 128. See Michelle Meadows, Managing Chronic Pain, FDA CONSUMER, Mar.–Apr. 2004, at 23, 27 
(―Addiction is characterized by craving and compulsive use of drugs.‖).  
 129. See Jeffrey Fudin et al., Chronic Pain Management with Opioids in Patients with Past or 
Current Substance Abuse Problems, 16. J. PHARMACY PRAC. 291, 294–95, 303 (2003).  
 130. See id.  
 131. See id. at 292, 293–94; see also Andrew Kolodny et al., Cautious, Responsible Opioid 
Prescribing, ADDICTION MED. UNIT, N.Y. ST. OFF. ALCOHOLISM & SUBSTANCE ABUSE SERVICES, 
http://www.oasas.ny.gov/admed/rx/documents/OpioidPrescribing.pdf (last visited Mar. 29, 2013) 
(indicating the importance of disclosing past and current drug before initiating opioid therapy). 
 132. See Kolodny et al., supra note 131. 
 133. See Jane C. Ballantyne, Opioid Analgesia: Perspectives on Right Use and Utility, 10 PAIN 
PHYSICIAN 479, 484, 486–87 (2007) (stating that patients with a personal or family history of drug abuse 
require increased monitoring). 
 134. Id. at 485. 
 135. Id. 
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early refills, simultaneous abuse of alcohol, doctor shopping, and prescription 
forgery.136  
Again, these outcomes do not affect all chronic pain patients. Rather, some 
opioid-treated patients develop tolerance without addiction,137 so patients need to 
make sure they keep an accurate and detailed record of their drug usage and its 
effects.138  
Being forthcoming and cooperative is especially useful if patients fear that 
their physician or other healthcare provider may suspect addiction when that is not 
necessarily the case.139 A drug diary allows physicians and other healthcare 
providers to track trends and adjust dosage according to effectiveness, particularly 
if a patient has moved or changed physicians.140 However, if the physician shows 
signs of fearing potential addiction, patients can also bring along a friend or family 
member as their supportive advocate to reassure the medical provider that drug-
seeking behaviors have not developed.141  
B.  Advice for Physicians and Other Healthcare Providers 
Since patients and their families might not always be able to recognize the 
difference between tolerance (which is acceptable in chronic pain patients) and 
addiction (which is not), it is important that physicians and other healthcare 
providers are themselves clear on the difference.142 Since the misconception that 
tolerance and addiction are the same is the source of unwarranted fears among 
 
 136. See generally CIGNA BEHAVIORAL HEALTH, TIPS FOR ADDRESSING POTENTIAL MEDICATION 
ABUSE IN PAIN PATIENTS (2006), available at http://www.cignabehavioral.com/web/basicsite/ 
provider/treatingBehavioralConditions/narcoticArticlePCPNewsletter.pdf (noting that patient behaviors 
such as increased use of opiates, doctor shopping, concurrent use of alcohol, early refills, and 
―scamming‖ are indicative of drug abuse). 
 137. See Jette Højsted et al., Classification and Identification of Opioid Addiction in Chronic Pain 
Patients, 14 EUR. J. PAIN 1014, 1014 (2010) (noting that according to one health organization, addiction 
diagnosis requires three out of six factors, of which increased tolerance is only one, to be present). 
 138. See Andrea M. Trescot et al., Opioid Guidelines in the Management of Chronic Non-Cancer 
Pain, 9 PAIN PHYSICIAN 1, 18, 28 (2006); Fudin et al., supra note 129, at 294–95 (emphasizing the 
importance of patients keeping detailed information on drug usage). 
 139. See AM. ACAD. OF PAIN MGMT., Advocating for a Loved One in Pain, NAT‘L FAM. 
CAREGIVERS ASS‘N, http://65.36.182.14/caregiving_resources/aapm.cfm (last visited Mar. 29, 2013) 
(suggesting ways that patients and patient advocates can more effectively insist on treatment to manage 
pain).  
 140. Chronic Pain Management: An Appropriate Use of Opioid Analgesics, ACP INTERNIST EXTRA, 
Jan. 2008, at 6 (noting that a physician may require a patient using opioid therapy to keep a pain diary as 
a method to monitor pain treatment). 
 141. See AM. ACAD. OF PAIN MGMT., supra note 139. 
 142. See McCaffery& Ferrell, supra note 119, at 186 (noting that patients, their families, and the 
general public have serious misconceptions about opioid addiction); Portenoy & Savage, supra note 121 
(noting that physicians‘ misconceptions about opioid addiction result in the under-treatment of pain; it 
follows that physicians must be instructed properly in the difference between opioid addiction and 
tolerance).  
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patients and physicians alike, it is essential that this issue is addressed if chronic 
pain patients are to receive adequate care.143 
Physicians and other healthcare providers can use the following criteria to 
assess chronic pain patients prior to implementing opioid therapy, also known as 
the ―4 A‘s: analgesia, activities of daily living, adverse events, and aberrant drug-
taking behaviors.‖144 Other factors that healthcare providers should consider 
include: 
 Using a multidisciplinary approach to pain management in both 
pharmacological and non-pharmacological interventions (physical therapy, 
psychological interventions, alternative approaches, etc.) prior to actual 
prescription of opioids if patients fear potential addiction;145 
 Prescribing opioid medication for acute and/or chronic pain after 
determining the futility of alternative therapies and allowing the lowest 
effective dose of opioids but also watching not to under-medicate;146 
 Referencing guidelines regarding opioid use for chronic pain, such as the 
one published by the American Academy of Family Physicians147 or the 
Substance Abuse and Mental Health Services Administration;148 
 Assessing the patient‘s individual needs: the site, duration, intensity and 
quality, as well as the impact of pain; the individual‘s previous experiences 
with pain, disability, and emotional distress; possible history with substance 
abuse, comorbidities, and other behavioral factors;149 and 
 
 143. See id. (noting that unwarranted patient and physician fears about opioid addiction result in the 
under-treatment of chronic pain). 
 144. See Steven D. Passik, Issues in Long-term Opioid Therapy: Unmet Needs, Risks, and Solutions, 
84 MAYO CLINIC PROC. 593, 597 (2009). 
 145. See Ken Berkowitz & Robert D. Kerns, Remarks at the National Ethics Teleconference on 





 146. See Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain, supra note 122, at 
1 (describing the conditions under which opioid therapy should be prescribed).  
 147. See BARBARA L. BITTNER ET AL., AM. ACAD. OF FAMILY PHYSICIANS, USING OPIOIDS IN THE 
MANAGEMENT OF CHRONIC PAIN PATIENTS: CHALLENGES AND FUTURE OPTIONS 2 (2010), available at 
http://www.mc.uky.edu/equip-4-
pcps/documents/CRx%20Literature/Opioids%20for%20chronic%20pain.pdf. 
 148. Pain Management Without Psychological Dependence: A Guide for Healthcare Providers, IN 
BRIEF (Ctr. for Substance Abuse Treatment, U.S. Dep‘t of Health & Human Servs., Rockville, Md.), 
Summer 2006, at 1–3, available at http://www.kap.samhsa.gov/products/brochures/pdfs/saib_0401.pdf. 
 149. See Passik, supra note 144, at 594–95 (discussing factors that should guide physicians in 
choosing pain therapy for patients).  
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 Using a comprehensive assessment inclusive of patient history, related to 
medical, family, psychosocial, medication, and past interventions; physical 
examinations; diagnostic studies; and note of any underlying conditions.150 
Similarly, physicians and other healthcare providers should pay close 
attention to their patients‘ personal and family medical histories prior to prescribing 
opioids.151 However, this should not deter them from considering opioid therapy as 
an option for pain relief even among patients with substance abuse histories 
(personal or familial) for the reasons discussed earlier.152 Instead, following the 
introduction of opioid therapy, physicians and other healthcare providers should 
continue to keep careful record of their patients‘ dosages and the effects of 
treatment and be able to differentiate between tolerance and addiction.153 
To ensure that a patient‘s chronic pain is well controlled, without temptations 
for supplementation with alcohol or illegal drugs, physicians and other healthcare 
providers should question their chronic pain patient‘s on the following points: 
 Use of other substances, including prescription drugs from other physicians, 
alcohol or illicit drugs, and at what dosages, and how often154 
 Whether these substances are used by the individual to ease pain: physical, 
emotional, or in a social context155 
 What other effects the pain medications are having on the individual (e.g. 
feelings of euphoria, withdrawal symptoms when discontinued, unwanted 
side-effects)156 
Opioid therapy should be stopped or an alternative treatment plan developed 
if the pain resolves itself or if the opioid therapy no longer achieves its initial goals 
of easing pain, improving function, and/or enhanced quality of life, or if the patient 
exhibits symptoms of addiction.157 In order to avoid symptoms of withdrawal and 
rebound increases in pain, the use of opioids should be tapered off.158 
 
 150. Id. at 594. 
 151. See Ken Solis, Ethical, Legal, and Professional Challenges Posed By “Controlled Medication 
Seekers” to Healthcare Providers, Part 2, 7 AM. J. CLINICAL MED. 86, 87–88 (2010) (discussing the 
importance of recognizing warning signs for opioid dependence before prescribing). 
 152. See Passik, supra note 144, at 594–95 (recommending that individuals with a history of 
substance abuse consult a pain specialist or psychologist before beginning opioid therapy). 
 153. Id. at 597. 
 154. See Seddon R. Savage et al., Challenges in Using Opioids to Treat Pain in Persons with 
Substance Use Disorders, ADDICTION SCI. & CLINICAL PRAC., June 2008, at 4, 9 (discussing the 
importance of assessing other drug use prior to proscribing opioid treatment). 
 155. Id. at 16–17.  
 156. Id. at 9. 
 157. Several scholarly articles discuss situations that would warrant the curtailment of opioid 
treatment. See, e.g., Clark, supra note 13; Savage et al., supra note 154, at 22–23. 
 158. See Clark, supra note 13.  
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C.  Advice to Legislators and Other Regulatory Agencies 
In the past, the American healthcare system has ―failed to recognize chronic 
pain as a legitimate condition,‖ particularly among chronic pain patients.159 This is 
in part due to its association with other health disparities such as race, ethnicity, 
age, gender, and socioeconomic status.160 Thus, legislators and other agency 
members can help promote the adequate management of chronic pain by 
advocating for increased access to comprehensive assessments, greater coordinated 
care, and the research funding needed to identify new therapies and areas of clinical 
guidance.161  
Legislators, advocates, and policymakers have many options in terms of what 
they can do to help promote the adequate management of chronic pain patients. 
One option is working to amend privacy requirements to help limit disclosure of 
the fact that a particular patient is being treated with opioids to only the most 
necessary situations.162 These efforts can help patients be less hesitant to try opioids 
for pain management, but these privacy concerns need to be balanced against the 
need to share information that will help healthcare professionals more effectively 
exclude potential drug abusers, addicts, or dealers from obtaining drugs under the 
pretense of seeking treatment.163 Advanced information sharing could also help 
patients locate the best healthcare providers for chronic pain through the 
development and application of quality indicators and performance measures,164 but 
again, it is essential that any means implemented to achieve these goals avoid 
creating a chilling effect on chronic pain patients‘ willingness to seek treatment.165 
Another potential area for advocacy would be the reform of reimbursement 
practices for chronic pain. Currently, Medicare and Medicaid maintain fee-for-
service systems for reimbursement that inadequately compensate healthcare 
professionals for the time it requires ―to assess, counsel, and educate‖ which are 
 
 159. See MAY DAY FUND, A CALL TO REVOLUTIONIZE CHRONIC PAIN CARE IN AMERICA: AN 
OPPORTUNITY IN HEALTH CARE REFORM 4 (2010), available at http://www.maydaypainreport.org/ 
docs/A%20Call%20to%20Revolutionize%20Chronic%20Pain%20Care%20in%20America%2003.04.10
.pdf.  
 160. Id. 
 161. Id. at 10–11. 
 162. See Lianne Lian Hu et al., Privacy Protection for Patients with Substance Use Problems, 2 
SUBSTANCE ABUSE & REHABILITATION 227, 228 (2011) (discussing issues such as stigma and 
discrimination caused by inadequate privacy policies in the context of patients who have substance 
abuse problems). 
 163. See id.; MAY DAY FUND, supra note 159, at 10–11 (advocating for a ―balanced approach‖ to 
regulating opioids used for pain management).  
 164. See MAY DAY FUND, supra note 159, at 9 (recommending the development of advanced 
information sharing systems to monitor pain disorders, treatments and outcomes). 
 165. Although advanced information sharing could help patients locate the best healthcare provider, 
prescription monitoring can have a negative and possibly chilling effect on opioid prescription and use, 
as there are some concerns over patient privacy. See generally Hu et al., supra note 162 (discussing 
privacy concerns surrounding health information for patients who have substance abuse problems). 
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essential to the adequate treatment of chronic pain.166 The Department of Health 
and Human Services (HHS) should explore outcome-based payments and the use of 
team approaches to treatment to help assure proper assessment and follow-up for 
chronic pain patients.167 Such monetary incentives would also encourage healthcare 
professionals to take the time necessary to adequately assess and manage chronic 
pain.168 
Finally, advocates need to find a better approach to the regulation of 
controlled prescription drugs, particularly opioids. Legislation needs to clearly 
distinguish between dependency or tolerance in the medical context and addiction 
and the problems it causes.169 Furthermore, there needs to be an education 
campaign to teach healthcare professionals, regulators, law enforcement, and the 
general public that opioid use per se is not wrong or a social evil, that such drugs 
can help normalize the lives of chronic pain patients, and that the amount of drug 
prescribed alone is not an indicator of abuse, but an indicator of individual patient 
needs and tolerances for the medication.170  
Quasi-government organizations, such as state medical boards (and 
accreditation organizations indirectly), can also exercise influence over pain 
management policies.171 In particular, they can work to encourage the training of 
healthcare professionals in pain assessment and treatment.172 Since states have the 
ability to set the standards and/or appoint those who set standards for medical 
licensing and discipline, they can look towards incorporating more pain 
management content on licensing exams.173  
III.  CONCLUSION 
Now is the time to remove both social and legal barriers to adequate chronic 
pain management. According to a report from the Institute of Medicine, more than 
100 million Americans suffer from chronic pain and many more family members, 
friends, and colleagues suffer with them because of the irritability, depression, and 
loss of productivity caused by uncontrolled pain.174 It is estimated that the under-
 
 166. See MAY DAY FUND, supra note 159, at 10. 
 167. Id. 
 168. Id. 
 169. See interview by Jennifer Lobb with Jennifer Schneider (Apr. 2005) (transcript available at 
http://www.jenniferschneider.com/articles/addiction-tolerance-dependence.html) (commenting on the 
―widespread misunderstanding‖ of the differences between dependency or tolerance and addiction). 
 170. See id.; Hoffmann & Tarzian, supra note 105, at 22–23 (discussing the evolution of opioid pain 
treatment and concluding that state medical boards are still looking for the ―right balance‖ in promoting 
and regulating opioid therapies).  
 171. See MAY DAY FUND, supra note 159, at 9 (proposing pain care training changes through state 
medical boards, professional schools, and residency training programs). 
 172. Id. 
 173. Id. at 9–11. 
 174. INST. OF MED., supra note 16, at 1. 
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treatment of chronic pain costs our country $600 billion a year in other medical 
treatments and lost productivity.175 We can no longer afford to ignore such a 
wasteful expenditure of healthcare dollars and such a needless loss of quality of 
life. We need to start by helping the public, medical professionals, and 
governmental actors understand that the proper medical management of opioid use 
for the treatment of chronic pain has none of the negative social side effects 
associated with addiction or illegal drug use. Second, laws, regulations, and 
enforcement practices need to accurately reflect this distinction and even actively 
encourage the effective management of chronic pain without stigmatizing the 
healthcare professionals involved in providing such care, the family members who 
seek help for their loved ones, or the patients who take opioids or other controlled 
substances to manage their pain. Finally we can all do our part by educating 
ourselves and advocating for those suffering from chronic pain. 
 
 
 175. Boyles, supra note 6. 
